retatrutide clinical trial us Retatrutide, an experimental drug currently in Phase 3 trials, is nicknamed the Godzilla of weight-loss jabs because of its potential superior efficacy. Developed by Eli Lilly, is a triple hormone Retatrutide Shows 28% Weight Loss
Description
Most patients reach Wegovy HD around 45 months after starting treatment
As bariatric and nutritional specialists, we often see patients make the same mistake
doi: 10.1042/BJ20050113
In June 2019, The FDA approved liraglutide for the treatment of pediatric patients over the age of 10 years with T2D
Similarly, Rezaie holds GLP-1s prior to elective endoscopic procedures, including colorectal cancer screening, since their use may affect gastric motility and colonoscopy prep
J Diabetes 8(5):701711
